Brenda Vincenzi, MD, is Head of Clinical Development at Oak Hill Bio, where she leads the clinical advancement of rugonersen for Angelman syndrome. Prior to joining Oak Hill Bio, she held senior clinical development roles at uniQure and Hoffmann-La Roche, leading global neuroscience programs in Angelman syndrome, autism spectrum disorder, schizophrenia, and other neurodevelopmental and psychiatric conditions.

Dr. Vincenzi received her medical degree and completed her residency in Child and Adolescent Neuropsychiatry at the University of Verona. She subsequently held academic and clinical research positions at institutions including Massachusetts General Hospital and the University Hospital Zurich before transitioning to industry drug development.